Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beijing Kaixiang Hongkang Biotechnology Co. Ltd. has 1 pending office action in the Chemistry & Materials technology area. This action is assigned to 1 distinct examiner and is located within 1 distinct art unit. This reflects a specific and concentrated prosecution focus for the company's current filings. The concentration of 1 pending office action in a single unit indicates that the company is not currently managing a diverse docket of active cases at the USPTO.
The busiest examiner for the company is BEISNER, WILLIAM H, who is managing 1 pending office action. Since the total number of pending actions is 1, this examiner is the only one currently reviewing the company's active applications. The presence of 1 distinct art unit and 1 distinct examiner for the 1 pending office action suggests that the company's current intellectual property strategy is focused on a single technical innovation in the Chemistry & Materials field.
Practitioners should focus on the specific requirements of BEISNER, WILLIAM H to advance the 1 busiest examiner pending case. The data reflects a portfolio that is not yet diversified across multiple 1 distinct art units or examiners. This centralized prosecution requires careful attention to the feedback from the assigned examiner, as the outcome of the 1 pending office action will be the primary determinant of the company's immediate success.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BEISNER, WILLIAM H | 1 | 61.9% | +29.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18363722 | AUTOMATED APPARATUS FOR EFFECTIVELY ENRICHING NEUROGENIC EXOSOMES IN BLOOD | BEISNER, WILLIAM H | — |
| Art Unit | Apps |
|---|---|
| 1799 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18363722 | AUTOMATED APPARATUS FOR EFFECTIVELY ENRICHING NEUROGENIC EXOSOMES IN BLOOD | BEISNER, WILLIAM H | 1799 | §112 | Final Rejection | — | Pending | Aug 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeijing Kaixiang Hongkang Biotechnology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
William H Beisner has the most, with 1 of Beijing Kaixiang Hongkang Biotechnology Co. Ltd.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
